 Xenograft Model Antitumor Assays
"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.
| Descriptor ID |
D023041
|
| MeSH Number(s) |
E05.337.550.200.900 E05.624.850
|
| Concept/Terms |
Xenograft Model Antitumor Assays- Xenograft Model Antitumor Assays
- Tumor Xenograft Assay
- Xenograft Antitumor Assays
- Antitumor Assay, Xenograft
- Antitumor Assays, Xenograft
- Assay, Xenograft Antitumor
- Assays, Xenograft Antitumor
- Xenograft Antitumor Assay
- Antitumor Assays, Xenograft Model
|
Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".
Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".
This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 5 | 5 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 2 | 2 | | 2005 | 0 | 5 | 5 | | 2006 | 2 | 4 | 6 | | 2007 | 0 | 4 | 4 | | 2008 | 2 | 10 | 12 | | 2009 | 1 | 14 | 15 | | 2010 | 1 | 12 | 13 | | 2011 | 2 | 12 | 14 | | 2012 | 2 | 23 | 25 | | 2013 | 2 | 19 | 21 | | 2014 | 0 | 18 | 18 | | 2015 | 2 | 23 | 25 | | 2016 | 3 | 20 | 23 | | 2017 | 1 | 35 | 36 | | 2018 | 2 | 25 | 27 | | 2019 | 1 | 25 | 26 | | 2020 | 1 | 30 | 31 | | 2021 | 0 | 12 | 12 | | 2022 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2024 | 5 | 15 | 20 | | 2025 | 0 | 6 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.
-
Cimons JM, DeGolier KR, Burciaga SD, Yarnell MC, Novak AJ, Rivera-Reyes AM, Kohler ME, Fry TJ. T-bet overexpression enhances CAR T cell effector functions and antigen sensitivity. J Immunother Cancer. 2025 Apr 17; 13(4).
-
Souto EP, Gong P, Landua JD, Rajaram Srinivasan R, Ganesan A, Dobrolecki LE, Purdy SC, Pan X, Zeosky M, Chung A, Yi SS, Ford HL, Lewis MT. Lineage Tracing and Single-Cell RNA Sequencing Reveal a Common Transcriptional State in Breast Cancer Tumor-Initiating Cells Characterized by IFN/STAT1 Activity. Cancer Res. 2025 Apr 15; 85(8):1390-1409.
-
Pham-Danis C, Novak AJ, Danis E, McClellan SM, Leach L, Yarnell MC, Ebmeier CC, Tasian SK, Kohler ME. Restoration of LAT activity improves CAR T?cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer Cell. 2025 Mar 10; 43(3):482-502.e9.
-
Maurya SK, Jaramillo-G?mez JA, Rehman AU, Gautam SK, Fatima M, Khan MA, Zaidi MAA, Khan P, Anwar L, Alsafwani ZW, Kanchan RK, Mohiuddin S, Pothuraju R, Vengoji R, Chirravuri Venkata R, Natarajan G, Bhatia R, Atri P, Perumal N, Chaudhary S, Lakshmanan I, Mahapatra S, Talmon GA, Cox JL, Smith LM, Santamaria-Barria JA, Ganti AK, Siddiqui JA, Cittelly DM, Batra SK, Nasser MW. Mucin 5AC Promotes Breast Cancer Brain Metastasis through cMET/CD44v6. Clin Cancer Res. 2025 Mar 03; 31(5):921-935.
-
Porazzi P, Nason S, Yang Z, Carturan A, Ghilardi G, Guruprasad P, Patel RP, Tan M, Padmanabhan AA, Lemoine J, Fardella E, Zhang Y, Pajarillo R, Chen L, Ugwuanyi O, Markowitz K, Delman D, Angelos MG, Shestova O, Isshiki Y, Blanchard T, B?guelin W, Melnick AM, Linette GP, Beatty GL, Carreno BM, Cohen IJ, Paruzzo L, Schuster SJ, Ruella M. EZH1/EZH2 inhibition enhances adoptive T?cell immunotherapy against multiple cancer models. Cancer Cell. 2025 Mar 10; 43(3):537-551.e7.
-
Ma J, Wang Z, Mintzlaff D, Zhang H, Ramakrishna R, Davila E, Witkowski MT, Lucia MS, Schwartz MS, Pomfret EA, Mathes DW, Wang Z. Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia. Blood. 2025 Jan 30; 145(5):508-519.
-
Balestra T, Niswander LM, Bagashev A, Loftus JP, Ross SL, Chen RK, McClellan SM, Junco JJ, B?rcenas L?pez DA, Rabin KR, Fry TJ, Tasian SK. Co-targeting of the thymic stromal lymphopoietin receptor to decrease immunotherapeutic resistance in CRLF2-rearranged Ph-like and Down syndrome acute lymphoblastic leukemia. Leukemia. 2025 Mar; 39(3):555-567.
-
Song X, Zhou Z, Elmezayen A, Wu R, Yu C, Gao B, Minna JD, Westover KD, Zeh HJ, Kroemer G, Heasley LE, Kang R, Tang D. SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. Sci Adv. 2024 Dec 13; 10(50):eadq4274.
-
Sala R, Esquer H, Kellett T, Clune S, Awolade P, Pike LA, Zhou Q, Messersmith WA, LaBarbera DV. CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models. Int J Mol Sci. 2024 Dec 07; 25(23).
-
Lin JJ, Horan JC, Tangpeerachaikul A, Swalduz A, Valdivia A, Johnson ML, Besse B, Camidge DR, Fujino T, Yoda S, Nguyen-Phuong L, Mizuta H, Bigot L, Nobre C, Lee JB, Yu MR, Mente S, Sun Y, Kohl NE, Porter JR, Shair MD, Zhu VW, Felip E, Cho BC, Friboulet L, Hata AN, Pelish HE, Drilon A. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov. 2024 Dec 02; 14(12):2367-2386.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|